Pivotal B-Well data show a significant 19% functional cure in the overall study population and 26% in patients with lower viral activity.
GSK will present new data from its expanding oncology portfolio and pipeline at ASCO and EHA.
First RSV vaccine approved for adults aged 18-59 years at increased risk and for all adults 60 years and older in Japan
Bepirovirsen is a potential first-in-class treatment for chronic hepatitis B, under priority regulatory review in China
Patient preference and adherence research highlight potential of long-acting dosing regimens to improve clinical outcomes in severe asthma
Breakthrough Therapy Designation added to Fast Track Designation, recognising potential for substantial improvement over existing treatments
Designations recognise potential for efimosfermin to address significant unmet medical need & reflect momentum in GSKs liver health pipeline
Delaware Chancery Court has granted the motion to dismiss filed by AnaptysBio, Inc. against TESARO’s claim for anticipatory breach.
As the only anti-BCMA approved in 2L+ multiple myeloma in China, Blenrep provides a new and needed mechanism of action in therapy.
GSK today announced the completion of its previously announced acquisition of 35Pharma Inc.
Promising efficacy and safety profile supports start of five pivotal phase III trials in 2026.
Exdensur is the first and only ultra-long-acting biologic in China for CRSwNP
Exdensur is the first and only ultra-long-acting biologic in China for the treatment of severe asthma with an eosinophilic phenotype.
Submission supported by statistically significant and clinically meaningful functional cure rates in pivotal Phase III B-Well trials
Submission supported by statistically significant and clinically meaningful functional cure rates in pivotal PhIII B-Well trials
Designation supported by early clinical data showing durable responses in certain types of small-cell lung cancer (SCLC).
Approval based on the positive GLISTEN phase III trial with regulatory reviews underway in the EU, UK, Canada and China
In the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection
GSK welcomes independent recognition of our leadership in addressing the urgent global threat of antimicrobial resistance (AMR).
GSK and Alfasigma today announced a licence agreement under which Alfasigma will acquire worldwide exclusive rights to linerixibat
GSK plc (LSE/NYSE: GSK) today announced the completion of its previously announced acquisition of RAPT Therapeutics